Who shouldnt use these peptides: Anyone with active cancer or a recent cancer history (GH and IGF-1 can stimulate growth of some malignancies) Severe uncontrolled diabetes, GH worsens insulin resistance Active proliferative diabetic retinopathy Pregnancy or breastfeeding Children or adolescents (growth plates still open) FDA 503A and what changed for sermorelin compounding This is the part of the conversation most clinic-marketing pages avoid, and it matters enough that you should know it before you start.In late 2023, the FDA reclassified sermorelins bulk substance status, removing it from the 503A compounding pathway that traditional compounding pharmacies operate under
Our approach involves adjusting medication doses to optimize blood sugar control while minimizing the risk of hypoglycemia
doi:10.1111/j.1432-1033.1997.00273.x
C.PavliO.FlemetakisE
Meyerhoff JL, Lee JK, Rittase BW, Tsang AY, Yourick DL
Only two of the thirteen residues differ from the native human hormone: norleucine replaces the oxidation-prone methionine at position 4, and the phenylalanine at position 7 is inverted to its D-enantiomer inside the conserved His-Phe-Arg-Trp message tetrapeptide